DIN 02361825 — REVOLADE 25 MG
REVOLADE is a tablet of Eltrombopag marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Eltrombopag monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02361825
- Brand name
- REVOLADE
- Active ingredient
- Eltrombopag
- Strength
- 25 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Thrombopoietin receptor agonist
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Eltrombopag products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02506742 | APO-ELTROMBOPAG | 25 MG | TABLET | APOTEX INC | MARKETED |
| 02506769 | APO-ELTROMBOPAG | 50 MG | TABLET | APOTEX INC | MARKETED |
| 02361833 | REVOLADE | 50 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |